Edition:
United Kingdom

People: Cyclacel Pharmaceuticals Inc (CYCC.OQ)

CYCC.OQ on NASDAQ Stock Exchange Capital Market

0.53USD
16 Sep 2019
Change (% chg)

-- (--)
Prev Close
$0.53
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
75,658
52-wk High
$1.73
52-wk Low
$0.28

Henney, Christopher 

Dr. Christopher S. Henney, Ph.D., D.Sc., serves as Independent Vice Chairman of the Board of Cyclacel Pharmaceuticals Inc., Dr. Henney has served as a director of the Company since March 2006. Dr. Henney had served as a director of Xcyte Therapies Inc., acquired by the Company in 2006, since March 2005, and continued on as Vice Chairman of the Company. Previously, Dr. Henney co-founded three major publicly held U.S. biotechnology companies, Immunex, ICOS and Dendreon, and held a seat on the board of directors and executive positions at each company. From 1995 to January 2003, Dr. Henney was Chairman and Chief Executive Officer of Dendreon Corporation. Dr. Henney currently serves as the Chairman, Interim President and CEO of Oncothyreon, Inc. and as the Chairman of Anthera Pharmaceuticals, Inc., both biotechnology companies. He is also a director of Prothena Corporation plc. He previously served as a director of Mymetics Inc. during 2011. Dr. Henney received a Ph.D. in experimental pathology from the University of Birmingham and a D.Sc. from the same university for contributions to the field of immunology. In 2012, Dr. Henney was inducted into the International Biotechnology CEOs Hall of Fame.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --